| The JV will be involved with a non-infringing and proprietary novel drug delivery (NDDS) form of an approved anti-cancer product for global markets. |
| As per the JV pact, both companies will undertake a core development programme and are initiating clinical trials for product registration in leading pharmaceutical markets for potential treatment of multiple types of cancer. The annual global sales of the currently available dosage form in this segment is likely to reach $500 million. |
| Zydus and Bharat Serums have also developed a global development programme to maximise the commercial potential of the product. |
| With evidence of safety and anti-tumour activity in a variety of cancer models in animals, this NDDS product has demonstrated competitive advantages that could differentiate it from the currently available dosage form. The product has been approved by the Drug Controller General of India (DCGI) for commercialisation in India. |
| Speaking on the joint initiative, Pankaj R Patel, chairman and managing director, Zydus, said the future of the oncology market will be driven by novel drug delivery systems offering improved efficacy, better safety and improved tolerability profile resulting in optimal therapy for patients. |
| "The NDDS product has demonstrated scientific evidences to deliver these differentiating features for commercial success in global pharmaceutical markets. This collaboration with BSV complements our strategic focus on developing innovative injectable oncology products and highlights our commitment to global oncology markets," he said. |
| Bharat Serums is currently one of the top ten biotech companies in India with an active R&D focus on biopharmaceuticals. About the JV with Zydus, Bharat Daftary said that it would leverage the strengths of the two companies and combine efforts to offer a novel antic therapy to patients globally. |
Top Section
Explore Business Standard